Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra |
| |
Authors: | T Diab M R Allen D B Burr |
| |
Institution: | (1) Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA;(2) Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN, USA;(3) Department of Biomedical Engineering, Indiana University—Purdue University at Indianapolis, Indianapolis, IN, USA;(4) Department of Anatomy and Cell Biology, MS 5035 Indiana University School of Medicine, 635 Barnhill Dr., Indianapolis, IN 46202, USA;(5) Present address: Parker H. Petit Institute for Bioengineering and Bioscience, 315 Ferst Drive Georgia Institute of Technology, Atlanta, GA 30332-0405, USA; |
| |
Abstract: | Summary We aimed to determine whether trabecular bone in sites that have different surface-based remodeling rates, the femoral neck
and vertebra, are differently affected by alendronate treatment. Alendronate treatment resulted in similar levels of turnover
in both sites, suggesting that a lower limit of bone turnover suppression with alendronate may exist.
Introduction Bone turnover suppression in sites that already have a low surface-based remodeling rate may lead to oversuppression that
could have negative effects on the biomechanical properties of bone. The goal was to determine how alendronate suppresses
bone turnover at sites with different surface-based remodeling rates.
Methods Dynamic histomorphometric parameters were assessed in trabecular bone of the femoral neck and lumbar vertebrae obtained from
skeletally mature beagles treated with saline (1 ml/kg/day) or alendronate (ALN 0.2 or 1.0 mg/kg/day). The ALN0.2 and ALN1.0
doses approximate, on a milligram per kilogram basis, the clinical doses used for the treatment of postmenopausal osteoporosis
and Paget’s disease, respectively.
Results Alendronate treatment resulted in similar absolute levels of bone turnover in the femoral neck and vertebrae, although the
femoral neck had 33% lower pre-treatment surface-based remodeling rate than the vertebra (p < 0.05). Additionally, the high dose of alendronate (ALN 1.0) suppressed bone turnover to similar absolute levels as the
low dose of alendronate (ALN 0.2) in both sites.
Conclusions Alendronate treatment may result in a lower limit of trabecular bone turnover suppression, suggesting that sites of low pre-treatment
remodeling rate are not more susceptible to oversuppression than those of high pre-treatment remodeling rate. |
| |
Keywords: | Animal models Anti-remodeling Bisphosphonates Histomorphometry |
本文献已被 SpringerLink 等数据库收录! |
|